SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on March 25, 2021. The registrant is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM. The report serves as a Regulation FD disclosure regarding a corporate presentation.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a disclosure event and does not contain audited or unaudited financial statements.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document solely announces a scheduled presentation by the Chairman and CEO.
Guidance, Outlook, and Management Commentary
Kenneth L. Londoner, Chairman and CEO, presented a slide deck at the Benzinga Biotech Small Cap Conference on March 25, 2021. The presentation is attached as Exhibit 99.1. The Company explicitly states it undertakes no obligation to update, supplement, or amend the materials in the presentation. The information provided is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Key Facts for Investor Verification
- Verify the content of the slide presentation (Exhibit 99.1) for any forward-looking statements or strategic updates, as the 8-K text itself contains no operational data.
- Confirm that the presentation materials are not legally binding or incorporated by reference into the Company's other SEC filings.
- Note that the filing date (March 25, 2021) is historical; investors should seek more recent 10-K or 10-Q filings for current financial status.